Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 86Colonic Neoplasms 32Rectal Neoplasms 31Neoplasms 24Pancreatic Neoplasms 22Stomach Neoplasms 20Neoplasm Metastasis 20Esophageal Neoplasms 20Neuroblastoma 12Glioma 11Sarcoma 9Glioblastoma 9Small Cell Lung Carcinoma 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Adenocarcinoma Of Esophagus 8Rhabdomyosarcoma 7Lung Neoplasms 7Sarcoma, Ewing 6Gliosarcoma 6Esophageal Squamous Cell Carcinoma 6Medulloblastoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Digestive System Diseases 4Adenocarcinoma 4

Interventions

regorafenib 1napabucasin 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Gastrointestinal Cancer × Irinotecan × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡